Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
NCT04906421
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
168
Enrollment
INDUSTRY
Sponsor class
Conditions
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Interventions
DRUG:
TVB-2640
OTHER:
Placebo
Sponsor
Sagimet Biosciences Inc.